The first stock of cell culture medium: OperMai rose 60% on the first day, and the market value exceeded 10 billion

On September 2, 2022, Opumai was officially listed on the Science and Technology Innovation Board, and its stock price has risen by 60% so far, with a market value of 10.

China's cell culture media market is still dominated by imported products, and the three major suppliers of Thermo Fisher Scientific (Gibco brand), Danaher (HyClone brand) and Merck account for two-thirds of the market share, and there is huge

Cell culture media for antibodies and protein drugs, imported products are generally 200-300 yuan / liter, and domestic products are generally about

According to data from the consulting body, the market size of China's antibody and protein drug cell culture media in 2020 is about

Thermo Fisher Scientific, Danaher, Merck accounted for two-thirds of the domestic media market, if specific to the field of antibodies and protein drugs, the share of the three foreign companies reached 81.

From 2019 to 2021, Opome's operating income increased rapidly from 26.

summary

China's biomedical industry is in a new era of vigorous development, commercialization is also in the beginning, and the international boom will come